CytomX Therapeutics, Inc. ã¯ãç±³åœã§è
«çåŠã«éç¹ã眮ãããã€ãªå»è¬åäŒæ¥ãšããŠäºæ¥ãå±éããŠããŸããå瀟ã¯ãããæ²»ççšã® Probody ãã¯ãããžãŒ ãã©ãããã©ãŒã ã«åºã¥ããŠæäœæ²»çè¬ãéçºããŠããŸããå瀟ã®è£œååè£ã«ã¯ãä¹³ããã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšäžã® CD166 ã«å¯Ÿããæäœè¬ç©è€åäœ (ADC) CX-2009ãæå¹³äžç®éå°çްèèºãããé é žéšæå¹³äžç®ãããé£éããããã³èé£éæ¥åéšãããã³ãŸãæ§å€§çްèå B 现èãªã³ãè
«ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšäžã® CX-2029ã転移æ§é»è²è
«ã®æ²»çè¬ãšããŠç¬¬ I/II çžèšåºè©Šéšäžã® CTLA-4 Probody æ²»çè¬ BMS-986249 ãªã©ããããŸããããã³æCTLA-4ããããã£è¬BMS-986288ã¯ãåºåœ¢è
«çã®æ²»çè¬ãšããŠç¬¬Içžèšåºè©Šéšäžã§ãããŸããäžç®çŽ°èæ¥çååãæšçãšããæ¡ä»¶ä»ã掻æ§åADCã§ããCX-2043ãããã³åºåœ¢è
«çã®æ²»çè¬ãšããŠæ¡ä»¶ä»ã掻æ§åäžç®æé·å åå容äœã§ããCX-904ãéçºããŠããŸããå瀟ã¯ãããããã£æ²»çè¬ã®éçºã«ãããŠãAbbVie Ireland Unlimited CompanyãAmgen, Inc.ãBristol-Myers Squibb CompanyãImmunoGen, Inc.ãPfizer Inc.ãããã³Astellas Pharma Inc.ãšæŠç¥çææºãçµãã§ããŸããCytomX Therapeutics, Inc.ã¯2008幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµãŠã¹ãµã³ãã©ã³ã·ã¹ã³ã«æ¬ç€Ÿã眮ããŠããŸãã